Preliminary analysis was performed to assess human health risks of exposure to 16 polycyclic aromatic hydrocarbons (PAHs) by way of inhalation by children and adults living in urban area of Amritsar, Punjab, India. In particular, the United States Environmental Protection Agency's (USEPA's) 16 priority PAH compounds were analyzed in air particulate matter (PM10) from different geographical locations by high-volume air sampler. Sum concentrations of PAHs (37-274 ng m(-3)) were comparable with those of other cities in India as well many cities on a global scale. Pyrene, naphthalene, acenaphthene, acenaphthylene, fluoranthene, fluorene, and dibenzo(a,h)anthracene accounted for >80% of ∑16PAH concentrations. Furthermore, the contribution of seven carcinogenic PAHs accounted for 12% of ∑16PAHs. The estimated carcinogenicity of PAHs in terms of benzo(a)pyrene toxic equivalency (BaPTEQ) was assessed and confirmed that dibenzo(a,h)anthracene was the dominant PAH contributor (88.7%) followed by benzo(a)pyrene (6.67%). Homolog pattern and diagnostic ratios of PAHs suggested that mixed pyrogenic sources--including biomass burning, coal combustion, and petrogenic sources, such as vehicular emissions--are dominant PAH sources in Amritsar. Health risk of adults and children by way of PAHs was assessed by estimating the lifetime average daily dose (LADD) and corresponding incremental lifetime cancer risk (ILCR) using USEPA guidelines. The assessed cancer risk (ILCR) was found to be within the acceptable range (10(-6)-10(-4)).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00244-013-9912-6 | DOI Listing |
Asian Pac J Cancer Prev
January 2025
Research Center for Vaccine and Drugs, The National Research and Innovation Agency (BRIN), South Tangerang 15310, Indonesia.
Objective: The progress made in cancer immunology has led to the development of innovative therapeutic strategies. However, despite these advances, the superficial characteristics of immune cells have been frequently overlooked: This oversight may be attributed to a limited understanding of the intricate relationships between immune cells and their microenvironment. This study seeks to address this limitation by comprehensively examining cell size and granularity in breast cancer (BC) patients and healthy donors (HD).
View Article and Find Full Text PDFJ Contemp Dent Pract
October 2024
Department of Prosthodontics, Dr. D.Y. Patil Dental College and Hospital, Dr. D.Y. Patil Vidyapeeth, Pune, Maharashtra, India.
Aim: The current investigation aimed to evaluate the accuracy of ultrasonography and color Doppler performed in the diagnosis of intraosseous jaw lesions.
Materials And Methods: A total of 30 patients with intraosseous jaw lesions between the ages of 12 and 60 were selected for the present study. For every jaw lesion, a preliminary diagnosis was done using preoperative conventional radiographs.
Genet Med
January 2025
Lipids and Atherosclerosis Laboratory, Department of Medicine and Dermatology, Centro de Investigaciones Médico Sanitarias (CIMES), Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA -Plataforma Bionand), University of Málaga, Málaga, Spain; Lipid Unit. Internal Medicine Service. University Hospital Virgen de la Victoria, Málaga, Spain.
Purpose: Genetic testing is required to confirm a diagnosis of familial chylomicronemia syndrome (FCS). We assessed the pathogenicity of variants identified in the FCS canonical genes to diagnose FCS cases.
Methods: 245 patients with severe hypertriglyceridemia underwent next-generation sequencing.
Front Immunol
January 2025
Department of Neurology, The First Affiliated Hospital of China Medical University, Shenyang, China.
Introduction: Efgartigimod has been approved for the treatment of acetylcholine receptor antibodies-positive generalized myasthenia gravis (AChR-Ab+gMG), but its efficacy in patients with ocular myasthenia gravis (OMG) is not known.
Case Presentation: We describe 2 cases of patients with AChR-Ab+ OMG who showed unfavorable responses to corticosteroids and tacrolimus. Within 2 weeks of initiating efgartigimod, both patients showed rapid improvement and minimal symptom expression was achieved in weeks 3 to 4, which was maintained up to week 12.
Open Res Eur
January 2025
Neuromotor Behavior and Exercise, University of Münster, Münster, Germany.
Background And Objectives: This is a protocol for a living systematic review and meta-analysis.This review will assess the effects of state-of-the-art exercise interventions designed to promote functional mobility. Therefore, after identifying all potential interventions, we will use the F.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!